Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Santen Pharmaceutical (TYO: 4536) announced that the New Drug Application (NDA) for its atropine sulfate...
Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody
Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD‑1005 project will...
Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System
Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system,...
TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb
TenNor Therapeutics (HKG: 6872) today announced positive top‑line results from its Phase IIa proof‑of‑concept clinical...
MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has...
China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
According to Yicai, the 2026 national healthcare security negotiations will officially kick off in Beijing...
Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug,...
Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with...
Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China’s...
Yipinhong’s AR882 Meets Primary Endpoint in Phase 3 Gout Trial, Outperforming Febuxostat on Uric Acid Reduction
Yipinhong Pharmacy Group Co., Ltd (SHE: 300723) announced that its Phase 3 trial for the...
AbbVie’s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig,...
Stoke and Biogen to Present 5-Year Zorevunersen Data in Dravet Syndrome at European Epilepsy Congress
Stoke Therapeutics (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced that they will present clinical...
Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases
Typewriter Therapeutics announced the completion of a USD 56 million Series A financing to develop...
NMPA Approves Eisai’s Lecanemab Subcutaneous Autoinjector for Early Alzheimer’s Disease in China
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that China’s National Medical...
Kanghong’s Conbercept Wins NMPA Approval for Fifth Indication in Retinopathy of Prematurity (ROP)
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that China’s National Medical Products Administration...
Simcere’s Culevibart Wins NMPA Approval as China’s RSV Prevention Monoclonal Antibody Yingmule
Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category...
GenScript Proposes ProBio Spin-Off for Standalone Listing on HKEX Main Board
Genscript Biotech Corporation (HKG: 1548) announced that it proposes to spin off its indirect non-wholly-owned...
Sino Biopharmaceutical’s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors
Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed...
Fosun Pharma’s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib...
Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a...